TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation balticbusinessnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from balticbusinessnews.com Daily Mail and Mail on Sunday newspapers.
Ojemba is an oral, brain-penetrant, highly-selective type II RAF kinas inhibitor designed to target a key enzyme in the MAPK signaling pathway. Ojemda is the first FDA-approved systemic therapy for pediatric LGG patients with BRAF rearrangements, including fusions.
HARMONi and HARMONi-3 Enrollment Continues
Promising Intracranial Anti-Tumor Activity and Safety Data Featured at the 2024 European Lung Cancer Congress with Ivonescimab Alone or Combined with.
APCCC 2024: Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice? urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
Ojemba is an oral, brain-penetrant, highly-selective type II RAF kinas inhibitor designed to target a key enzyme in the MAPK signaling pathway. Ojemda is the first FDA-approved systemic therapy for pediatric LGG patients with BRAF rearrangements, including fusions.